Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation [scRNA-seq]

ABSTRACT: Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation [scRNA-seq]

PROVIDER: PRJNA843082 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19431985.fastq.gz	Fastqsanger.gz
	SRR19431986.fastq.gz	Fastqsanger.gz
	SRR19431987.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation

Project description:Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation

| PRJNA843074 | ENA

Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation [CRISPR]

Project description:Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation [CRISPR]

| PRJNA788749 | ENA

Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation [CRISPR]

Project description:Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adaptor of a Cullin-3 RING E3 ubiquitin ligase complex responsible for degradation of RAS GTPases. In parallel, dysregulated LZTR1 expression via aberrant splicing and mutations have been identified in clonal hematopoietic conditions. Here we identify that loss of LZTR1, or leukemia-associated mutants in the LZTR1 substrate and RAS GTPase RIT1 which escape degradation, drive hematopoietic stem cell expansion (HSC) and leukemia in vivo. LZTR1 null cells rely on multiple RAS GTPases for transformation. Consequently, RAS targeting bioPROTACs or reduction of GTP-loaded RAS overcomes LZTR1 loss-mediated resistance to FLT3 inhibitors. These data thereby reveal proteolysis of non-canonical RAS proteins as novel regulators of HSC function, define the function and spectrum of RIT1 and LZTR1 mutations in leukemia, and identify means to overcome drug resistance due to LZTR1 downregulation.

2022-07-17 | GSE190857 | GEO

Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation [scRNA-seq]

2022-07-17 | GSE205016 | GEO

Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-07-16 | GSE205018 | GEO

Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.

Project description: Not available

| S-EPMC9533010 | biostudies-literature

RIT1 drives lung oncogenic transformation and is an actionable target in lung adenocarcinoma [PDX]

Project description:RIT1 is a small GTPase of the RAS family and RIT1 mutations have been identified in lung cancer, leukemias, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased levels of this oncoprotein due to impaired proteolysis, resulting in dysregulation of RAS/MAPK and other pathways. Here we document the diversity of RIT1 mutations in human lung cancer and show that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Due to the current lack of targeted therapies for this oncoprotein, we undertake different and complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway. Through a proof-of-concept chemical biology approach, we discover that RAS tri-complex inhibitors bind directly to GTP-bound RIT1 and lead to tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors.

2025-05-08 | GSE290503 | GEO

RIT1 drives lung oncogenic transformation and is an actionable target in lung adenocarcinoma [H2110]

2025-05-08 | GSE290502 | GEO

Targeted proteolysis of the histone H3 tail facilitates epigenetic reprogramming during differentiation

Project description:Though limited proteolysis of the histone H3 N-terminal tail (H3NT) is frequently observed during mammalian differentiation, however the specific genomic sites targeted for H3NT proteolysis and their functional significance of H3NT cleavage remain unknown.We used genome wide Chip-seq (ChIPac-Seq) approaches to an established cell model of osteoclast differentiation. We discovered that H3NT proteolysis is selectively targeted near transcription start sites of a small group of genes and that most of these H3NT-cleaved genes are epigenetically regulated during osteoclastogenesis.We also discovered that the principal H3NT protease of osteoclastogenesis is matrix metalloproteinase 9 (MMP-9).Abrogation of H3NT proteolysis impaired osteoclastogenic gene activation concomitant with defective osteoclast differentiation. In summary our results support the necessity of MMP-9-dependent H3NT proteolysis in the epigenetic reprogramming of gene pathways required for proficient osteoclastogenesis.

2016-02-02 | GSE72957 | GEO

p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.

Project description: Not available

| S-EPMC5323099 | biostudies-literature